The clinical relevance of PI3K pathway deregulation should be evaluated in the context of breast cancer molecular subtypes as these subtypes differ in survival outcome, treatment response, and frequency of PIK3CA mutations and PTEN loss [6],[15]–[18]. This evidence concerns the gene PIK3CA and breast carcinoma.